Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 efzofitimod trial in pulmonary sarcoidosis
NL-OMON53570Phase 3Not yet recruiting
- Sponsor
- aTyr Pharma
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efzofitimod in pulmonary sarcoidosis and sarcoidosis (3 arms), sponsored by aTyr Pharma. Primary endpoint: Primary efficacy endpoint. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosissarcoidosis
Beyond the preview
Go deeper on NL-OMON53570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53570.